California State Teachers Retirement System Has $20.68 Million Stake in Moderna, Inc. $MRNA

California State Teachers Retirement System lifted its stake in Moderna, Inc. (NASDAQ:MRNA) by 16.8% in the first quarter, HoldingsChannel.com reports. The firm owned 407,190 shares of the company’s stock after purchasing an additional 58,529 shares during the quarter. California State Teachers Retirement System’s holdings in Moderna were worth $20,685,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. MUFG Securities EMEA plc bought a new stake in shares of Moderna during the second quarter worth $28,000. Flagship Harbor Advisors LLC acquired a new stake in Moderna in the fourth quarter worth about $31,000. Canton Hathaway LLC bought a new stake in Moderna during the 1st quarter worth about $31,000. Cromwell Holdings LLC lifted its position in Moderna by 39.7% during the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock valued at $35,000 after purchasing an additional 341 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Moderna by 148.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after purchasing an additional 801 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of recent research reports. Piper Sandler boosted their price target on shares of Moderna from $69.00 to $77.00 and gave the stock an “overweight” rating in a research note on Friday, June 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Moderna in a research note on Friday, June 12th. The Goldman Sachs Group lifted their target price on shares of Moderna from $49.00 to $67.00 and gave the stock a “neutral” rating in a report on Tuesday, July 21st. Wolfe Research reiterated an “underperform” rating and set a $25.00 target price on shares of Moderna in a research report on Monday, July 20th. Finally, Royal Bank Of Canada upped their target price on shares of Moderna from $38.00 to $45.00 and gave the company a “sector perform” rating in a research report on Tuesday, July 7th. Two research analysts have rated the stock with a Buy rating, ten have given a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Moderna currently has a consensus rating of “Reduce” and an average target price of $40.00.

Insider Activity at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the sale, the insider owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. This represents a 4.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Noubar Afeyan sold 9,263 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $46.84, for a total transaction of $433,878.92. Following the completion of the sale, the director owned 3,924 shares in the company, valued at approximately $183,800.16. This trade represents a 70.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 119,406 shares of company stock worth $5,928,762. 10.80% of the stock is currently owned by company insiders.

Moderna Price Performance

Moderna stock opened at $54.82 on Friday. The firm has a market capitalization of $21.75 billion, a P/E ratio of -6.86 and a beta of 0.94. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $85.60. The business has a 50-day moving average of $59.37 and a 200-day moving average of $52.51. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. The company had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.Moderna’s revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the business posted ($2.13) EPS. On average, equities analysts anticipate that Moderna, Inc. will post -6.41 EPS for the current year.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported second-quarter EPS of -$1.97, better than the roughly -$2.03 consensus and an improvement from -$2.13 a year earlier. Revenue was approximately $145 million, while management reiterated its plan for up to 10% revenue growth in 2026. Moderna Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: The company improved its 2026 operating-expense outlook by about $200 million and now expects year-end cash of $4.7 billion to $5.2 billion, supporting its effort to reduce cash burn. Moderna also faces a potentially important catalyst on August 5, when regulators are scheduled to decide on its seasonal flu vaccine candidate, mFLUSIVA. Moderna Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Trading activity showed elevated interest in Moderna call options, with 82,913 contracts acquired versus a typical daily volume of 48,590. This may indicate speculative bullish positioning, but options activity alone does not establish a sustained change in investor sentiment.
• Negative Sentiment: Moderna’s Phase 3 mRNA-1403 norovirus vaccine trial did not meet the statistical criteria for early success at its interim analysis. The company plans to add another participant cohort, extending the trial into a fourth season and delaying clarity on a potential commercial opportunity. Moderna Adds New Cohort to Phase III Vaccine Trial
• Negative Sentiment: Investors remain concerned about Moderna’s dependence on declining COVID-19 vaccine sales. Although the quarterly loss narrowed, the company still posted a GAAP net loss of about $782 million, and reports characterized revenue as weaker than Wall Street expected. The norovirus setback therefore outweighed the earnings and cost-control improvements. Moderna Misses Quarterly Revenue Estimates on COVID Vaccine Weakness

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.